Eton Pharmaceuticals, Inc.
ETON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.7% | 9.5% | 48.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 35% | 63% | 57.1% | 55.6% |
| EBITDA | $0 | -$0 | $0 | $0 |
| % Margin | 1.2% | -2.5% | 3.1% | 8.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.6% | -13.7% | -9.1% | -5.1% |
| EPS Diluted | -0.07 | -0.096 | -0.059 | -0.023 |
| % Growth | 27.2% | -64.3% | -155.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |